The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.

about

LYVE-1 is 'on stage' now: an emerging player in dendritic cell docking to lymphatic endothelial cells.Integrin Activation: Implications for Axon Regeneration.Eosinophils from Physiology to Disease: A Comprehensive Review.

P2860

Q49615032-AF76BC61-2D1A-40E4-B278-F53D35ACCAB7 Q55058190-B5DFD6DD-02F1-409D-B513-517820765308 Q55311740-8384B482-0D0A-454E-B308-852939352095

P2860

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.

Item

http://www.wikidata.org/entity/Q40061894

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.

@en

type

Item

label

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.

@en

prefLabel

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.

@en

P1476

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.

@en

P2093

Barry A Singer

http://www.w3.org/2001/XMLSchema#string

P2860

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Clinical relevance of brain volume measures in multiple sclerosis.

Extended interval dosing of natalizumab in multiple sclerosis.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.

Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy.

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

P304

327-336

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756285617716002

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28861122

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

5557182

http://www.w3.org/2001/XMLSchema#string

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.

about

P2860

P2860

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932